These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 33387249)

  • 21. Searching possible SARS-CoV-2 main protease inhibitors in constituents from herbal medicines using
    Rasul HO; Thomas NV; Ghafour DD; Aziz BK; Salgado M G; Mendoza-Huizar LH; Candia LG
    J Biomol Struct Dyn; 2024 May; 42(8):4234-4248. PubMed ID: 37349945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from
    Al-Karmalawy AA; Alnajjar R; Elmaaty AA; Binjubair FA; Al-Rashood ST; Mansour BS; Elkamhawy A; Eldehna WM; Mansour KA
    J Biomol Struct Dyn; 2024 Aug; 42(13):6941-6953. PubMed ID: 37505066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M
    Ibrahim MAA; Abdelrahman AHM; Mohamed TA; Atia MAM; Al-Hammady MAM; Abdeljawaad KAA; Elkady EM; Moustafa MF; Alrumaihi F; Allemailem KS; El-Seedi HR; Paré PW; Efferth T; Hegazy MF
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33916461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
    Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational Approach toward COVID-19's Main Protease Inhibitors: A Hierarchical Biochemoinformatics Analysis.
    Bastos RS; de Aguiar CPO; Cruz JN; Ramos RS; Kimani NM; de Souza JSN; Chaves MH; de Freitas HF; Pita SSR; Santos CBRD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
    Yuda GPWC; Hanif N; Hermawan A
    Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease.
    de Oliveira Só YA; Bezerra KS; Gargano R; Mendonça FLL; Souto JT; Fulco UL; Pereira Junior ML; Junior LAR
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.
    Rakib A; Nain Z; Sami SA; Mahmud S; Islam A; Ahmed S; Siddiqui ABF; Babu SMOF; Hossain P; Shahriar A; Nainu F; Emran TB; Simal-Gandara J
    Brief Bioinform; 2021 Mar; 22(2):1476-1498. PubMed ID: 33623995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease.
    Sur VP; Sen MK; Komrskova K
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening of Potential Inhibitors Targeting the Main Protease Structure of SARS-CoV-2 via Molecular Docking, and Approach with Molecular Dynamics, RMSD, RMSF, H-Bond, SASA and MMGBSA.
    da Fonseca AM; Caluaco BJ; Madureira JMC; Cabongo SQ; Gaieta EM; Djata F; Colares RP; Neto MM; Fernandes CFC; Marinho GS; Dos Santos HS; Marinho ES
    Mol Biotechnol; 2024 Aug; 66(8):1919-1933. PubMed ID: 37490200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.